Groesbeck Investment Management Corp NJ Sells 3,400 Shares of AbbVie Inc. $ABBV

Groesbeck Investment Management Corp NJ decreased its holdings in AbbVie Inc. (NYSE:ABBV) by 51.9% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,155 shares of the company’s stock after selling 3,400 shares during the quarter. AbbVie accounts for approximately 1.4% of Groesbeck Investment Management Corp NJ’s holdings, making the stock its 25th biggest holding. Groesbeck Investment Management Corp NJ’s holdings in AbbVie were worth $731,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in the business. Brighton Jones LLC raised its holdings in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in AbbVie during the first quarter worth $383,000. Caxton Associates LLP bought a new position in shares of AbbVie during the first quarter valued at $1,347,000. Finally, MBB Public Markets I LLC acquired a new stake in shares of AbbVie in the 1st quarter valued at $314,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Berenberg Bank raised AbbVie to a Buy, providing an analyst-driven demand tailwind that can support near-term share gains. AbbVie (ABBV) Receives a Buy from Berenberg Bank
• Positive Sentiment: Multiple reports (WSJ/Reuters) said AbbVie was in advanced talks to acquire Revolution Medicines, fueling takeover speculation that typically lifts a buyer’s stock ahead of any deal announcement. AbbVie Near Deal for Revolution Medicines AbbVie in talks to buy biotech Revolution Medicines, WSJ reports
• Positive Sentiment: AbbVie expanded its oncology pipeline with a first‑in‑human ABBV‑901 trial in ovarian cancer — a pipeline development that supports longer‑term growth narratives beyond legacy assets. AbbVie Expands Ovarian Cancer Pipeline With New ABBV‑901 Trial
• Neutral Sentiment: Revolution Medicines shares jumped on the takeover rumors (market context), which contributed to intraday volatility in AbbVie-related news flow but doesn’t change AbbVie’s fundamentals unless a deal is announced. Revolution Medicines stock surges over 20%
• Neutral Sentiment: AbbVie scheduled its full‑year and fourth‑quarter 2025 earnings release and conference call for Feb. 4 — a routine event that will be the next formal opportunity for management to set expectations and move the stock. AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
• Neutral Sentiment: UBS reiterated a Hold rating, highlighting a balanced risk/reward given AbbVie’s premium valuation versus long-duration growth — a reminder that some analysts see limited upside from here. AbbVie: Premium Valuation… Hold Rating
• Negative Sentiment: AbbVie updated guidance: Q4 2025 EPS 3.320–3.360 and FY2025 EPS 10.610–10.650, each nudging slightly under consensus — a conservative tilt that can cap upside and explain some profit‑taking. (Company guidance released 1/8/2026)
• Negative Sentiment: After takeover reports, AbbVie publicly denied talks to buy Revolution Medicines, which may roll back some of the acquisition-driven rally and increase short-term volatility. Abbvie denies WSJ report of talks to buy Revolution Medicines
• Negative Sentiment: Competitive pressure: J&J’s Tremfya outspent AbbVie’s Skyrizi on TV ads through December, underscoring intense competition in immunology that can pressure market share and pricing over time. Tremfya outstrips Skyrizi in TV ad spend

Analyst Ratings Changes

Several equities analysts recently issued reports on ABBV shares. Hsbc Global Res raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Guggenheim lifted their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a report on Wednesday, October 8th. Berenberg Bank raised AbbVie from a “hold” rating to a “buy” rating and raised their price target for the company from $170.00 to $270.00 in a report on Wednesday, September 17th. Finally, Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus target price of $246.89.

AbbVie Stock Up 4.3%

AbbVie stock opened at $233.65 on Thursday. The business’s 50-day simple moving average is $226.63 and its 200 day simple moving average is $214.80. The stock has a market cap of $412.95 billion, a price-to-earnings ratio of 177.01, a P/E/G ratio of 0.94 and a beta of 0.36. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. During the same period in the prior year, the company posted $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is presently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.